|Systematic (IUPAC) name|
|Molar mass||175.23 g/mol[[Script error: No such module "String".]]|
6-(2-aminopropyl)benzofuran or 1-benzofuran-6-ylpropan-2-amine (6-APB) is a stimulant and entactogen drug of the phenethylamine and amphetamine classes. It is an analogue of MDA where the 3,4-methylenedioxyphenyl ring system has been replaced with a benzofuran ring. 6-APB is also the unsaturated benzofuran derivative of 6-APDB. There is currently no toxicology data availble and there is no history of human use.
6-APB has not been properly assayed in terms of pharmacological action, but based on its effects and chemical similarity to other amphetamines, it likely acts as a releasing agent of serotonin, norepinephrine, and dopamine. Though its effects on monoamine release have not been validated, 6-APB has been shown to act as an agonist of the 5-HT2C receptor. It may also act as an agonist of the 5-HT2A and 5-HT2B receptors, the former likely explaining its psychedelic effects.
Certain countries contain a "substantially similar" catch all clause in their drug law, such as New Zealand and Australia. This includes 6-APB as it is in some respects similar in chemical structure to the class A drug MDA, meaning 6-APB is likely to be viewed as a controlled substance analogue in these jurisdictions.
Canada - Controlled under item 1 of Schedule III of the CDSA.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />